AMENDMENT AND EXCHANGE AGREEMENTAmendment and Exchange Agreement • April 22nd, 2020 • Ocugen, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 22nd, 2020 Company Industry JurisdictionThis AMENDMENT AND EXCHANGE AGREEMENT (the “Agreement”) is made as of April 22, 2020, by and among Ocugen, Inc., a Delaware corporation formerly known as Histogenics Corporation (the “Company”), Ocugen OpCo, Inc., a Delaware corporation formerly known as Ocugen, Inc. (“OpCo”), and the investor signatory hereto (the “Investor”).